# Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

> **NCT00878254** · PHASE2 · COMPLETED · sponsor: **University of Miami** · enrollment: 25 (actual)

## Conditions studied

- Mantle-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** G-CSF
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **DRUG:** Leucovorin
- **DRUG:** Mesna
- **DRUG:** Methotrexate
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT00878254
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-25
- **Primary completion:** 2024-06-28
- **Final completion:** 2025-05-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00878254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00878254, "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00878254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*